-
公开(公告)号：US11597725B2
公开(公告)日：2023-03-07
申请号：US16617426
申请日：2018-05-25
发明人： Dongfang Shi , Jianghua Zhu , Jie Gu , Xi Cheng , Yan Yang , He Zhou , Pengfei Li , Fan Wu
IPC分类号： C07D471/04 , A61P19/06 , C07D231/56 , C07D487/04 , C07D491/052
摘要： The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.
-
公开(公告)号：US10399971B2
公开(公告)日：2019-09-03
申请号：US15758866
申请日：2016-09-08
发明人： Dongfang Shi , Changjin Fu , Xi Cheng , Jianghua Zhu , Jie Wen , Jie Gu
IPC分类号： C07D471/04 , A61K31/437 , A61P19/06
摘要： The invention discloses a class of compounds for treating or preventing hyperuricemia or gout, which is a compound shown in general formula (I) or a pharmaceutically acceptable salt. These compounds and their pharmaceutically acceptable salts in the invention are useful for the promotion of uric acid excretion to treat or prevent hyperuricemia or gout.
-
公开(公告)号：US11643405B2
公开(公告)日：2023-05-09
申请号：US16973443
申请日：2019-06-05
发明人： Dongfang Shi , Changjin Fu , Xi Cheng , Weiwei Gong , Jie Gu , Pengfei Li , Min Zhang , Yan Yang , Wenqing Jin
IPC分类号： C07D407/04 , A61P1/16 , A61K9/00 , A61K9/08
CPC分类号： C07D407/04 , A61P1/16 , A61K9/0053 , A61K9/08
摘要： The invention discloses compounds for treatment or prevention of liver diseases. The compounds are compounds represented by a formula (I) or (II), optical isomers or pharmaceutically acceptable salts of the compounds. The compounds and optical isomers or pharmaceutically acceptable salts of the compounds can be applied to preparation of drugs for treatment or prevention of liver diseases.
-
公开(公告)号：US20240262808A1
公开(公告)日：2024-08-08
申请号：US18557919
申请日：2022-04-28
发明人： Dongfang SHI , Changjin FU , Yan YANG
IPC分类号： C07D403/04 , A61K31/416 , A61K31/4192 , A61K31/4439 , A61P19/06 , C07D231/56 , C07D401/04 , C07D405/14 , C07D409/04
CPC分类号： C07D403/04 , A61K31/416 , A61K31/4192 , A61K31/4439 , A61P19/06 , C07D231/56 , C07D401/04 , C07D405/14 , C07D409/04
摘要： It discloses a compound shown in general formula (1) or a pharmaceutically acceptable salt thereof and a method for preparation of the compound; the compound is a xanthine oxidase inhibitor with xanthine oxidase inhibiting activity; the compound has an excellent xanthine oxidase inhibitory activity and has potential application value in anti-gout drugs, anti-hyperuricemia drugs, etc.
-
公开(公告)号：US10005744B2
公开(公告)日：2018-06-26
申请号：US15572760
申请日：2016-05-06
发明人： Dongfang Shi , Changjin Fu , Xi Cheng , Jianghua Zhu
IPC分类号： A61K31/41 , C07D293/12 , A61P35/00
CPC分类号： C07D293/12 , A61K31/41 , A61P35/00
摘要： It discloses compounds for the treatment and prevention of breast cancer, which are specifically 2-phenyl benzoselenazole compounds, pharmaceutically acceptable salts thereof and prodrugs thereof. The present invention further discloses pharmaceutical compositions containing the compounds and applications of the compounds in preparing medicines for the treatment and prevention of breast cancer in mammals. The compounds of the present invention can effectively inhibit or reduce the growth or proliferation of breast cancer cells in mammals, with no inhibition effect on the growth of part of the tested cell lines except for the breast cancer cell lines, and are highly selective.
-
公开(公告)号：USRE50083E1
公开(公告)日：2024-08-20
申请号：US17707795
申请日：2022-03-29
发明人： Dongfang Shi , Changjin Fu , Xi Cheng , Jianghua Zhu , Jie Gu
IPC分类号： C07D487/04 , A61P3/00 , C07D307/80 , C07D471/04 , C07D491/048 , C07D513/04
CPC分类号： C07D487/04 , A61P3/00 , C07D307/80 , C07D471/04 , C07D491/048 , C07D513/04
摘要： Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on hURAT1-transported uric acid in HEK293 transfected cells, and show that such compounds have a good potential for application in the treatment of hyperuricemia or gout.
-
公开(公告)号：US09802907B2
公开(公告)日：2017-10-31
申请号：US14648664
申请日：2013-11-24
发明人： Dongfang Shi , Changjin Fu , Jie Wu , Jun Liu
IPC分类号： C07D293/06 , C07D421/10 , A61K31/381 , A61K33/04 , A61K31/41 , A61K31/4365 , A61K31/4439 , A61K31/496 , A61K31/5377 , C07D421/12 , C07D495/04
CPC分类号： C07D293/06 , A61K31/41 , A61K31/4365 , A61K31/4439 , A61K31/496 , A61K31/5377 , C07D421/10 , C07D421/12 , C07D495/04
摘要： A 2-aryl selenazole compound and a pharmaceutical composition are disclosed, wherein the 2-aryl selenazole compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The 2-aryl selenazole compound has the activity of inhibiting xanthine oxidase. The compound or a pharmaceutically acceptable salt thereof can be applied in terms of preparing a drug used for prevention or treatment of hyperuricemia, gout, diabetic nephropathy, an inflammatory disease or a neurological disease.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
